HomeCompareJCYCF vs ABBV

JCYCF vs ABBV: Dividend Comparison 2026

JCYCF yields 4.15% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JCYCF wins by $10.0K in total portfolio value· pulled ahead in Year 9
10 years
JCYCF
JCYCF
● Live price
4.15%
Share price
$27.00
Annual div
$1.12
5Y div CAGR
36.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$113.7K
Annual income
$36,346.84
Full JCYCF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — JCYCF vs ABBV

📍 JCYCF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJCYCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JCYCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JCYCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCYCF
Annual income on $10K today (after 15% tax)
$352.38/yr
After 10yr DRIP, annual income (after tax)
$30,894.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, JCYCF beats the other by $9,368.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCYCF + ABBV for your $10,000?

JCYCF: 50%ABBV: 50%
100% ABBV50/50100% JCYCF
Portfolio after 10yr
$108.7K
Annual income
$30,835.81/yr
Blended yield
28.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JCYCF
No analyst data
Altman Z
2.4
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCYCF buys
0
ABBV buys
0
No recent congressional trades found for JCYCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJCYCFABBV
Forward yield4.15%3.09%
Annual dividend / share$1.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR36.4%40.6%
Portfolio after 10y$113.7K$103.7K
Annual income after 10y$36,346.84$25,324.79
Total dividends collected$84.6K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JCYCF vs ABBV ($10,000, DRIP)

YearJCYCF PortfolioJCYCF Income/yrABBV PortfolioABBV Income/yrGap
1$11,265$565.47$11,555$434.96$290.00ABBV
2$12,866$812.06$13,485$635.47$619.00ABBV
3$14,949$1,182.27$15,933$937.67$984.00ABBV
4$17,747$1,751.11$19,118$1,400.80$1.4KABBV
5$21,639$2,650.00$23,384$2,125.24$1.7KABBV
6$27,273$4,119.03$29,290$3,286.81$2.0KABBV
7$35,799$6,617.87$37,776$5,205.38$2.0KABBV
8$49,379$11,073.88$50,495$8,488.44$1.1KABBV
9← crossover$72,307$19,471.47$70,497$14,346.44+$1.8KJCYCF
10$113,716$36,346.84$103,718$25,324.79+$10.0KJCYCF

JCYCF vs ABBV: Complete Analysis 2026

JCYCFStock

Jardine Cycle & Carriage Limited, an investment holding company, engages in the automotive, financial services, heavy equipment, mining, construction and energy, agribusiness, infrastructure and logistics, information technology, and property businesses in Indonesia and internationally. The company produces, distributes, retails, and aftersales services of motor vehicles, as well as manufactures and distributes automotive components; manufactures, assembles, distributes, and owns dealership networks for Toyota, Daihatsu, Isuzu, Peugeot, and UD Trucks, as well as Honda motorcycles; and manufactures and retails BMW vehicles, and owns the Lexus cars dealership. It also offers financial services, such as financing for motorcycles, cars, heavy equipment, insurance protection for individual and commercial customers, lending products to retail consumers, and digital payment solutions. In addition, the company supplies heavy equipment and provides aftersales services for various sectors, including mining, plantation, construction, and forestry; distributes Komatsu, UD, SCANIA, Bomag, and Tadano heavy equipment; and owns and operates thermal and metallurgical coal, gold, and thermal power assets, as well as operates in the construction and renewable energy sectors. Further, it cultivates, harvests, and processes palm oil; develops and manages toll roads; provides printing and digital services solutions; and distributes FUJIFILM business products, as well as develops office and residential buildings. The company was formerly known as Cycle & Carriage Ltd. and changed its name to Jardine Cycle & Carriage Limited in 2004. The company was founded in 1899 and is based in Singapore. Jardine Cycle & Carriage Limited is a subsidiary of Jardine Strategic Singapore Pte Ltd.

Full JCYCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JCYCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCYCF vs SCHDJCYCF vs JEPIJCYCF vs OJCYCF vs KOJCYCF vs MAINJCYCF vs JNJJCYCF vs MRKJCYCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.